Skip to main content

News HP

Mon, 07/02/2018 - 15:00 - Fri, 07/02/2021 - 15:30
  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular v
Fri, 04/20/2018 - 08:30

Not to be distributed directly or indirectly in the United States, Canada, Australia or Japan

 

Thu, 04/05/2018 - 09:00
  • ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to c

Tue, 11/03/2015 - 17:00

IM Europe and Sofimac Partners are the main investors

 

Thu, 09/10/2015 - 17:00

Supported by ElsaLys Biotech, PX’Therapeutics, a subsidiary of the Aguettant group, and Centr

Thu, 07/02/2015 - 17:00
  • Developed so far by MABLIFE in ophthalmology, the anti-CD160 antibody has also a significant therapeutic potential in oncology.

Tue, 02/16/2016 - 17:00
  • Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property an

Thu, 12/15/2016 - 17:00
  • Initially developed by TRANSGENE, one of ELSALYS BIOTECH’s founding shareholders, this antibody inhibits a deleterious subpopulation of

Mon, 01/30/2017 - 17:00

After having recently enriched its pipeline of therapeutic antibodies in oncology, ElsaLys Biotech strengthens its management team with the arriva

Tue, 07/18/2017 - 17:00
  • With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation im

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter